EUVIMEDEUVIMED entdecken
Crossref

Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening

Safa Lotfi

Journal of Ophthalmic and Optometric Sciences · 08.11.2023

DOI: 10.22037/joos.v6i1.42856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ophthalmic and Optometric Sciences, erschienen am 08.11.2023. Verfasst von Safa Lotfi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic or topical administration of sulfonamide-containing carbonic anhydrase (CA) inhibitors is currently one of the lowering IOP approaches to treat glaucoma. Carbonic anhydrase II is an eye-expressed CA isoenzyme and has a major role in aqueous humor production. Material and Methods: To identify new CA II inhibitors, the receptor-based virtual screening was performed using DrugRep server and its FDA-approved drug library. The crystal structure of human CA II (3HS4) was utilized as the receptor. The physicochemical, pharmacokinetic, and drug-likeness properties of 15 top-ranked inhibitors were then investigated by SwissADME server.

Results

The results showed that 200 recognized inhibitors interact with CA II active site with high binding affinities (-10.1 to -7.2 kcal/mol). 9 out of 15 top compounds (antrafenine, doxycycline, sitagliptin, benzhydrocodone, lumacaftor, deferasirox, lemborexant, talazoparib, selinexor, enasidenib, rolapitant, cyclothiazide, bendroflumethiazide, chlorthalidone, and quinupramine) possess fluorine atoms and 3 of them have the sulfonamide group in their structure. Based on the results, deferasirox is suggested as a promising candidate for further studies. This moderately soluble compound, which does not have fluorine atoms or a sulfonamide group in its structure, exhibits high bioavailability and GI absorption. Deferasirox is not a blood-brain barrier permeant and P-glycoprotein substrate and does not inhibit any CYP isoforms.

Conclusion

Deferasirox is suggested as a good candidate for glaucoma treatment. However, many further studies are required in this regard.

Schlagwörter

deferasiroxcarbonic anhydrase IIglaucomaintraocular pressuresulfonamide inhibitorsaqueous humor productiondrug repurposingvirtual screeningADME propertiesdrug-likeness

Zitieren

APA

Lotfi, S. (2023). Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening. Journal of Ophthalmic and Optometric Sciences. https://doi.org/10.22037/joos.v6i1.42856

Vancouver

Lotfi S. Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening. Journal of Ophthalmic and Optometric Sciences. 2023. doi:10.22037/joos.v6i1.42856

BibTeX
@article{Lotfi2023,
  author = {Lotfi, Safa},
  title = {Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening},
  journal = {Journal of Ophthalmic and Optometric Sciences},
  year = {2023},
  doi = {10.22037/joos.v6i1.42856}
}
Kostenlos starten →